Sucharita Mistry, PhD

Longer overall survival with palbociclib plus fulvestrant was seen in most subgroups, but not in women who were endocrine resistant or had prior chemotherapy.

Patients treated with ribociclib and fulvestrant had prolonged OS compared to patients who received fulvestrant with placebo.

Adding dalpiciclib to fulvestrant significantly improved progression-free survival.

Patients who experienced immune-related adverse events had longer overall survival than those who did not in both the atezolizumab-containing and control arms.

First-line treatment with nivolumab in combination with ipilimumab and chemotherapy provided durable survival compared to chemotherapy alone in patients with NSCLC.

Progression-free and overall survival were superior in patients who received immunotherapy and chemotherapy.

Patients with chronic lymphocytic leukemia had a significantly reduced antibody response rate when compared with healthy individuals.

Researchers sought to investigate the long-term outcomes of ELIOT after conserving surgery in early-stage breast cancer compared with whole breast irradiation.